Abstract: A method of therapeutic treatment by genome engineering in a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5? to 3? an RNA Booster sequence that includes or is the following ribonucleic acid sequence: mmsknkkkm, wherein: m? indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest encoding at least one genome editor.
Abstract: A method of treating skin and/or skin appendages in a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5? to 3?: an RNA Booster sequence that includes or is the following ribonucleic acid sequence: mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest.
Abstract: A ribonucleic acid (RNA) that includes from 5? to 3?: an RNA Booster sequence that includes or is the following ribonucleic acid sequence: mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); n” indicates any nucleotide; and a sequence of interest. Also, methods for robust transient RNA expression.
Abstract: A method of vaccinating a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5? to 3?: an RNA Booster sequence that includes or is the following ribonucleic acid sequence mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest encoding at least one antigen.
© 2025 Justia
